Commission and Commissioner Public Statements and Letters

Show: 20 | 50 | 100
Displaying 20 results
Displaying 381 - 400 of 676


Joint FDA/FTC Warning Letter Concerning Product Labeling of Human Chrorionic Gonadotropin (HCG) Drugs

LaTonya Mitchell, Director, Food and Drug Administration (FDA) Denver District Office; and Dr. Ilisa Bernstein, Acting Director, FDA Office of Compliance to Dr. Gary Arbuckle and Ms. Amy Freeze, and


Mary K. Engle